Oberland Capital
Venture debtNew York · Growth–Late Stage · 20 people tracked
Also known as OBERLAND CAPITAL MANAGEMENT LLC
Investment thesis
Oberland Capital focuses on funding innovation across the global healthcare industry through flexible, customized investment structures. Its financing solutions include the monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. The firm aims to accelerate the development and commercialization of promising healthcare products to create value for partners and transform patient care.
Source: firm website, verified Aug 18, 2026.
Team · 20 people
from the firm's website
What they invest in
from 17 of 18 portfolio companiesBiotech ×15Healthtech ×11Medical Devices ×11Deep Tech ×3Digital Health ×3
HQs:United States×10Switzerland×1United Kingdom×1
Investments · 18 tracked
founders shown can be your intro pathBiotechHealthtechMedical DevicesLexington, US
Garo Armen(Executive Officer, Director)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)Karen Valentine(Executive Officer)
BoardBrian Corvese(Director)
Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSCommodore CapitalInvusLigand Pharmaceuticals+1 more
BillionToOne is a precision diagnostics company that uses molecular counting technology to develop non-invasive prenatal screening and liquid biopsy tests for early disease detection.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Oguzhan Atay, PhD(Co-Founder, CEO, and Board Chair)David Tsao, PhD(Co-Founder, CTO, and Board Member)Oguzhan Atay(Founder)inDavid Tsao(Founder/CTO)inSukrit Silas(Cofounder)
Co-investors500 Emerging EuropeAsymmetry VenturesCivilization Ventures Management, Llce2vcFifty YearsFriale+14 more
Biohaven is a biopharmaceutical company developing treatments in immunology, obesity, neuroscience, and oncology, with approved migraine therapies and a pipeline of early-to-late-stage drug development programs.
BiotechHealthtech
Co-investorsRA CapitalSixth Street
ClearPoint Neuro develops image-guided surgical systems that enable precise navigation to the brain and spine for neurosurgical procedures, drug delivery, and cell and gene therapy applications.
Deep TechHealthtechMedical Devices
Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform.
BiotechHealthtechMedical DevicesMorrisville, US
Laura E. Niklason(Director)Ted Lithgow(Executive Officer)Paul Boyer(Executive Officer)Carrie S. Cox(Executive Officer, Director)
BoardRobert Anderson(Director)Robert Langer(Director)
Co-investorsFirst In VenturesFresenius Medical Care Ventures
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders.
BiotechDeep TechDigital HealthHealthtechMedical DevicesRaleigh, US
BENJAMIN R. YERXA(Executive Officer, Director)George Magrath(Chief Executive Officer)Ben Yerxa(President)Robert Gagnon(Chief Financial Officer)Joe Schachle(Chief Operating Officer)Ash Jayagopal(Chief Scientific and Development Officer)
Co-investorsMichigan Capital Network
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergAMY C. CAVERS(Executive Officer)CATHY CAREW(Executive Officer)JONATHAN PACHTER(Executive Officer)ROB GAGNON(Executive Officer)BRIAN STUGLIK(Executive Officer, Director)
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLightstone VenturesLongwood FundOrbiMed
MeiraGTx is a clinical-stage genetic medicine company developing gene therapies for rare and prevalent diseases.
BiotechHealthtechMedical Devices
Co-investorsAlbionVCUCL Technology Fund
BiotechMiramar, US
Hing C Wong(Executive Officer, Director)Peter Rhode(Executive Officer)
BoardAdam Waldman(Director)Fred Middleton(Director)C. Boyder Gray(Director)
Co-investorsSanderling Ventures
Centessa is a pharmaceutical company focused on developing medicines for patients, emphasizing innovation and collaboration in drug development.
BiotechHealthtech
Co-investorsAdvent Life SciencesEcoR1 CapitalVida VenturesCambridge Innovation Capital
BiotechAnn Arbor, US
Antonio M. Gotto, Jr.(Director)Tim M. Mayleben(Executive Officer, Director)Gilbert S. Omenn(Director)Daniel Janney(Director)Dov A. Goldstein(Director)Nicole Vitullo(Director)
Co-investorsAisling CapitalAlta PartnersArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan Partners+2 more
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Sean George(Executive Officer, Director)Randal Scott(Executive Officer, Director)Shelly Guyer(Executive Officer)Lee Bendekgey(Executive Officer)Geoffrey Crouse(Director)
BoardEric Aguiar(Director)in
Co-investorsCivilization Ventures Management, LlcDecheng CapitalFifty YearsManta Ray VenturesPrefix CapitalTech Wildcatters+1 more
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsFrazier Life SciencesLongitude CapitalRiverVest Venture Partners
NorthStar develops non-reactor-based production processes for radiopharmaceuticals Cu-67 and Ac-225 used in cancer treatment.
BiotechMedical Devices
OXB is a contract development and manufacturing organization (CDMO) providing end-to-end services for cell and gene therapies, with expertise in lentiviral vectors, AAV, adenovirus, and other viral vector manufacturing.
BiotechDeep TechHealthtechOxford, GB
Co-investorsNovo Holdings
Co-investorsAvoro Capital AdvisorsKurma PartnersSunstone Capital
Exits · 8
IPOs and acquisitions across the tracked portfolioAgenusNASDAQ: AGENBillionToOneNASDAQ: BLLNBiohavenNYSE: BHVNClearpointneuroNASDAQ: CLPTHumacyteNASDAQ: HUMAOpus GeneticsNASDAQ: IRDVerastemNASDAQ: VSTMLumena Pharmaceuticalsacq. by Shire
Portfolio news
latest coverage across their companiesAgenus · simplywall.st · Aug 15, 2026
BillionToOne · investing.com · Jul 13, 2026
Verastem · insidermonkey.com · Jul 3, 2026
Centessa · streetinsider.com · Jun 24, 2026
Fund performance · per public LP disclosures · 3
as of Dec 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Oberland Capital Healthcare III LPLPs: Texas Municipal Retirement System | — | — | 2.9% | 1.11x | 0.19x |
| Oberland Capital Healthcare Solutions Co-Invest LPLPs: Texas Municipal Retirement System | — | — | 23.5% | 1.35x | 0.56x |
| Oberland Capital Healthcare Solutions LPLPs: Texas Municipal Retirement System | — | — | 10.6% | 1.22x | 0.58x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Oberland Capital made?
- Oberland Capital has 18 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does Oberland Capital invest at?
- Oberland Capital invests at the Growth, Late Stage stages.
- What is Oberland Capital's typical check size?
- Oberland Capital typically writes checks of $50M – $300M.
- What sectors does Oberland Capital focus on?
- Oberland Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Oberland Capital located?
- Oberland Capital is headquartered in New York, US.
- Who does Oberland Capital co-invest with?
- Oberland Capital most often shares deals with Advent Life Sciences, Civilization Ventures Management, Llc, Fifty Years, among 55 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.